
Computational Biologist @icmrnirrch
- Tweets22
- Following21
- Followers11
- Likes14

ALT • The novel repurposed antibacterial drug besifloxacin led to an 83% reduction of murine kidney fungal burden as compared to no-drug control. • It showed positive synergism with a lower than MIC dose of fluconazole (0.5 mg/L) proposing its use in combination therapy against Candida infections.

ALT Identification and Evaluation of Besifloxacin as Repurposed Antifungal Drug in Combination With Fluconazole Against Candida albicans ABSTRACT Emergence of life-threatening fungal Infections like systemic candidiasis concurrently with bacterial infections and limitations of current antifungal therapies warrant the discovery of novel inhibitors. We Identified besifloxacin (BS), an FDA-approved an-tibacterial, as a potent antifungal inhibitor. A combination of besifloxacin with fluconazole showed a positive synergy (8=29.58) resulting in 80% inhibition of microbial growth. BS was able to reduce the MIC of FLC from 2mg/L to 0.5mg/L when used in combination. Additionally, In murine systemic Candida Infection, BS reduced fungal load by 83% in mice kidneys at a dose of 100 mg/kg/day. The findings demonstrated the antifungal potential of BS, proposing its use in combination therapy with flucona-zole to combat resistance through alternative mechanisms.


































